House dust mite-induced allergic rhinitis

Allergen-Specific Immunotherapy
Specific immunotherapy may act by inducing a switch from T helper 2 cell response (Th2) to T helper 1 cell (Th1) response resulting in decreased interleukin-4 (IL-4) and interleukin-5 (IL-5) and increased interleukin-10 (IL-10), production of IgG-blocking antibodies that compete with IgE antibodies for allergen binding, proliferation of regulatory T lymphocytes and cytokines, and decreases in mast cells, eosinophils, and early- and late-phase allergic responses

1. Hypersensitivity to any component of the formulation
2. Severe, unstable, or uncontrolled asthma
3. History of any severe systemic allergic reaction
4. History of any severe local reaction after taking any sublingual allergen immunotherapy
5. History of eosinophilic esophagitis

1. In general, allergy immunotherapy may continue in women tolerating treatment who become pregnant after therapy has started.
2. However, initiating allergy immunotherapy during pregnancy is generally avoided

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk and benefits.

Common:
Pruritus of the ear, glossalgia, nausea, oral itching, stomach pain, swelling of lips, swollen tongue, tongue ulcer, mouth edema, pharyngeal edema, throat irritation, cough<20231213>
Postmarketing:
Erythema of skin, anaphylaxis, hypersensitivity reaction

(Sublingual) One tablet once daily

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.